

QUANTITY LIMIT CRITERIA

DRUG CLASS	ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AGENTS
BRAND NAME (generic)	
	ADDERALL (amphetamine mixture)
	ADDERALL XR (amphetamine extended-release mixture)
	ADZENYS ER (amphetamine extended-release oral suspension)
	ADZENYS XR-ODT (amphetamine extended-release orally disintegrating tablets)
	APTENSIO XR (methylphenidate extended-release)
	CONCERTA (methylphenidate extended-release)
	COTEMPLA XR-ODT (methylphenidate extended-release orally disintegrating tablets)
	DAYTRANA (methylphenidate transdermal system)
	DESOXYN (methamphetamine)
	DEXTROAMPHETAMINE PRODUCTS (dextroamphetamine)
	DEXEDRINE SPANSULE (dextroamphetamine sustained-release)
	DYANAVEL XR (amphetamine extended-release oral suspension)
	EVEKEO

(amphetamine sulfate)

**FOCALIN
(dexmethylphenidate)**

**FOCALIN XR
(dexmethylphenidate extended-release)**

**METADATE CD
(methylphenidate extended-release)**

**METHYLIN CHEWABLE TABLET
(methylphenidate chewable tablet)**

**METHYLPHENIDATE PRODUCTS
(methylphenidate)**

**METHYLPHENIDATE EXTENDED-RELEASE PRODUCTS
(methylphenidate extended-release)**

**MYDAYIS
(amphetamine mixture extended-release)**

**PROCENTRA
(dextroamphetamine sulfate oral solution)**

**QUILLICHEW ER
(methylphenidate extended-release chewable tablets)**

**QUILLIVANT XR
(methylphenidate extended-release oral suspension)**

**RITALIN LA
(methylphenidate extended-release)**

**STRATTERA
(atomoxetine)**

**VYVANSE
(lisdexamfetamine)**

**ZENZEDI
(dextroamphetamine)**

Status: CVS Caremark Criteria
Type: Quantity Limit

POLICY

FDA-APPROVED INDICATIONS

Adderall

Adderall is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy.

Adderall XR

Adderall XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Adzenys ER

Adzenys ER is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

Adzenys XR-ODT

Adzenys XR-ODT is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

Aptensio XR

Aptensio XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Concerta

Concerta is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 years of age and older, adolescents, and adults up to the age of 65.

Cotempla XR-ODT

Cotempla XR-ODT is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.

Daytrana

Daytrana is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Desoxyn

Desoxyn is indicated for Attention Deficit Disorder with Hyperactivity and Exogenous Obesity.

Dexedrine Spansule

Dexedrine Spansules are indicated for the treatment of Narcolepsy and Attention Deficit Disorder with Hyperactivity.

Dextroamphetamine

Dextroamphetamine is indicated for the treatment of Narcolepsy and Attention Deficit Disorder with Hyperactivity.

Dyanavel XR

Dyanavel XR is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Evekeo

Evekeo is indicated for Narcolepsy, Attention Deficit Disorder with Hyperactivity, and Exogenous Obesity.

Focalin

Focalin is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Focalin XR

Focalin XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged six years and older.

Metadate CD

Metadate CD is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Methylin Chewable Tablets

Methylin Chewable Tablets are indicated for Attention Deficit Disorders and Narcolepsy.

Methylphenidate/Methylphenidate Extended-release

Methylphenidate and methylphenidate extended-release are indicated for Attention Deficit Disorders and Narcolepsy.

Mydayis

Mydayis is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older.

ProCentra

ProCentra is indicated for the treatment of Narcolepsy and Attention Deficit Disorder with Hyperactivity.

QuilliChew ER

QuilliChew ER is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Quillivant XR

Quillivant XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Ritalin LA

Ritalin LA is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Strattera

Strattera is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).

Vyvanse

Vyvanse is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and moderate to severe Binge-Eating Disorder (BED).

Zenedi

Zenedi is indicated for Narcolepsy and Attention Deficit Disorder with Hyperactivity.

For all ADHD Agents:

Attention Deficit Hyperactivity Disorder (ADHD)

A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-V) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; "on the go;" excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met.

REFERENCES

1. Adderall [package insert]. Horsham, PA: Teva Pharmaceuticals USA; September 2016.
2. Adderall XR [package insert]. Wayne, PA: Shire US Inc.; December 2015.
3. Adzenys XR-ODT [package insert]. Grand Prairie, TX: Neos Therapeutics, LP.; February 2016.
4. Aptensio XR [package insert]. Coventry, RI: Rhodes Pharmaceuticals L.P.; October 2016.
5. Concerta [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; September 2015.
6. Daytrana [package insert]. Miami, FL: Noven Therapeutics, LLC; August 2016.
7. Desoxyn [package insert]. Lebanon, NJ: Recordati Rare Diseases Inc.; February 2015.
8. Dexedrine Spansule [package insert]. Horsham, PA: Amedra Pharmaceuticals, LLC; February 2015.
9. Dextroamphetamine sulfate [package insert]. Dayton, NJ: Aurolife Pharma LLC; September 2016.
10. Dyanavel XR [package insert]. Monmouth Junction, NJ: Tris Pharma, Inc.; December 2015.
11. Evekeo [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; February 2015.
12. Focalin [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2015.
13. Focalin XR [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2015.
14. Metadate CD [package insert]. Smyrna, GA: UCB, Inc.; February 2015.
15. Metadate ER [package insert]. Smyrna, GA: UCB, Inc.; February 2016.
16. Methylphenidate/Methylphenidate ER Tablets [package insert]. Hazelwood, MO: Mallinckrodt Inc.; April 2015.
17. Methylin Chewable Tablets [package insert]. Florham Park, NJ: Shionogi Inc.; December 2013.
18. Methylin Solution [package insert]. Florham Park, NJ: Shionogi Inc.; February 2015.
19. ProCentra [package insert]. Newport, KY: Independence Pharmaceuticals, LLC; September 2015.
20. QuilliChew ER [package insert]. Monmouth Junction, NJ: Tris Pharma, Inc.; February 2016.
21. Quillivant XR [package insert]. Monmouth Junction, NJ: Tris Pharma, Inc.; May 2016.
22. Ritalin/Ritalin SR [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2015.
23. Ritalin LA [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2015.
24. Strattera [package insert]. Indianapolis, IN: Eli Lilly and Company; April 2015.
25. Vyvanse [package insert]. Wayne, PA: Shire US Inc.; April 2015.
26. Zenedi [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; May 2015.
27. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed November 2016.
28. Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically. www.micromedexsolutions.com [available with subscription]. Accessed November 2016.
29. Practice Parameter for the Assessment and Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. *J Am Acad Child Adolesc Psychiatry*. 2007; 46(7):894-921. <http://www.jaacap.com/article/S0890-8567%2809%2962182-1/pdf>. Accessed November 2016.
30. American Academy of Pediatrics. ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. *Pediatrics*. 2011; 128(5):1007-1022. <http://pediatrics.aappublications.org/content/early/2011/10/14/peds.2011-2654>. Accessed November 2016.
31. Cotempla XR-ODT [package insert]. Grand Prairie, TX: Neos Therapeutics, Inc.; June 2017.
32. Mydayis [package insert]. Lexington, MA: Shire US Inc.; June 2017.
33. Adzenys ER [package insert]. Grand Prairie, TX: Neos Therapeutics, LP.; September 2017.

LIMIT CRITERIA

One limit allowed per each strength

	<u>1 Month Limit*</u>	<u>3 Month Limit*</u>
Adderall 5 mg, 7.5 mg, 10 mg, 12.5 mg	90 tabs/25 days	270 tabs/75 days
Adderall 15 mg, 20 mg	60 tabs/25 days	180 tabs/75 days
Adderall 30 mg	30 tabs/25 days	90 tabs/75 days
Adderall XR 5 mg, 10 mg	90 caps/25 days	270 caps/75 days

Adderall XR 15 mg, 20 mg, 25 mg, 30 mg	30 caps/25 days	90 caps/75 days
Adzenys ER oral suspension 1.25 mg/mL	450 mL/25 days	1350 mL/75 days
Adzenys XR-ODT 3.1 mg, 6.3 mg, 9.4 mg	60 tabs/25 days	180 tabs/75 days
Adzenys XR-ODT 12.5 mg, 15.7 mg, 18.8 mg	30 tabs/25 days	90 tabs/75 days
Aptensio XR 10 mg, 15 mg, 20 mg, 30 mg	60 caps/25 days	180 caps/75 days
Aptensio XR 40 mg, 50 mg, 60 mg	30 caps/25 days	90 caps/75 days
Concerta 18 mg, 27 mg, 36 mg	60 tabs/25 days	180 tabs/75 days
Concerta 54 mg	30 tabs/25 days	90 tabs/75 days
Cotempla XR 8.6 mg	60 tabs/25 days	180 tabs/75 days
Cotempla XR 17.3 mg, 25.9 mg	60 tabs/25 days	180 tabs/75 days
Daytrana Patch 10 mg, 15 mg, 20 mg, 30 mg	30 patches/25 days	90 patches/75 days
Desoxyn 5 mg	150 tabs/25 days	450 tabs/75 days
Dextroamphetamine 2.5 mg, 5 mg, 7.5 mg, 10 mg	120 tabs/25 days	360 tabs/75 days
Dextroamphetamine 15 mg, 20 mg	60 tabs/25 days	180 tabs/75 days
Dextroamphetamine 30 mg	30 tabs/25 days	90 tabs/75 days
Dexedrine Spansule 5 mg, 10 mg	120 caps/25 days	360 caps/75 days
Dexedrine Spansule 15 mg	60 caps/25 days	180 caps/75 days
Dyanavel XR oral suspension 2.5 mg/mL	240 mL/25 days	720 mL/75 days
Evekeo 5 mg, 10 mg	120 tabs/25 days	360 tabs/75 days
Focalin 2.5 mg, 5 mg	120 tabs/25 days	360 tabs/75 days
Focalin 10 mg	60 tabs/25 days	180 tabs/75 days
Focalin XR 5 mg, 10 mg, 15 mg, 20 mg	60 caps/25 days	180 caps/75 days
Focalin XR 25 mg, 30 mg, 35 mg, 40 mg	30 caps/25 days	90 caps/75 days
Metadate CD 10 mg, 20 mg, 30 mg	60 caps/25 days	180 caps/75 days
Metadate CD 40 mg, 50 mg, 60 mg	30 caps/25 days	90 caps/75 days
Methylin Chewable Tablets 2.5 mg, 5 mg or 10 mg	180 tabs/25 days	540 tabs/75 days
Methylphenidate 5 mg, 10 mg	180 tabs/25 days	540 tabs/75 days

Methylphenidate 20 mg	90 tabs/25 days	270 tabs/75 days
Methylphenidate oral solution 5 mg/5 mL	1800 mL/25 days	5400 mL/75 days
Methylphenidate oral solution 10 mg/5 mL	900 mL/25 days	2,700 mL/75 days
Methylphenidate ER 10 mg, 20 mg	90 tabs/25 days	270 tabs/75 days
Mydayis 12.5 mg, 25 mg	60 tabs/25 days	180 tabs/75 days
Mydayis 37.5 mg, 50 mg	30 caps/25 days	90 caps/75 days
ProCentra oral solution 5 mg/5 mL	1200 mL/25 days	3600 mL/75 days
QuilliChew ER 20 mg, 30 mg	60 tabs/25 day	180 tabs/75 days
QuilliChew ER 40 mg	30 tabs/25 days	90 tabs/75 days
Quillivant XR oral suspension 25 mg/5 mL (5 mg/1 mL)	360 mL/25 days	1080 mL/75 days
Ritalin LA 10 mg, 20 mg, 30 mg	60 caps/25 days	180 caps/75 days
Ritalin LA 40 mg, 60 mg	30 caps/25 days	90 caps/75 days
Strattera 10 mg, 18 mg, 25 mg	120 caps/25 days	360 caps/75 days
Strattera 40 mg	60 caps/25 days	180 caps/75 days
Strattera 60 mg, 80 mg, 100 mg	30 caps/25 days	90 caps/75 days
Vyvanse 10 mg, 20 mg, 30 mg	60 caps/25 days	180 caps/75 days
Vyvanse 40 mg, 50 mg, 60 mg, 70 mg	30 caps/25 days	90 caps/75 days
Zenzedi 2.5 mg, 5 mg, 7.5 mg, 10 mg	120 tabs/25 days	360 tabs/75 days
Zenzedi 15 mg, 20 mg	60 tabs/25 days	180 tabs/75 days
Zenzedi 30 mg	30 tabs/25 days	90 tabs/75 days

**The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.*